Biora Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Biora Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-92.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-92.2%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: BIOR şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: BIOR şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Biora Therapeutics Piyasaya Karşı Temettü Getirisi

BIOR temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (BIOR)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (BIOR) (3 yıla kadar)	n/a

Önemli Temettü: BIOR şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, BIOR şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: BIOR şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: BIOR herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Biora Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000002 million.

Athyrium Capital Engages in Discussions with Biora Therapeutics

Biora Therapeutics Announces Positive Nasdaq Listing Decision

Athyrium Capital Management Engages with Biora Therapeutics

Biora Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Biora Therapeutics, Inc. Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented At KOL Event

Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc

Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600

Biora Therapeutics Provides Non-Compliance Update

Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director

New major risk - Revenue and earnings growth

Biora Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose (Mad) Cohorts for Clinical Trial of BT-600

Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biora Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

New major risk - Share price stability

Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose (Sad) Cohorts of Phase 1 Clinical Study of BT-600

Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Consensus revenue estimates fall by 17%

Third quarter 2023 earnings released: US$4.89 loss per share (vs US$1.99 loss in 3Q 2022)

Biora Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Share price stability

Biora Therapeutics Presents Data on the Biojet™ Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Biora Therapeutics, Inc. (NasdaqGM:BIOR) acquired Interface Therapeutics Inc.

Biora Therapeutics Progresses Its BioJet™ Systemic Oral Delivery Platform

New major risk - Financial position

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biora Therapeutics, Inc. Announces New Patents Covering Its BioJet Systemic Oral Delivery Platform

Biora Therapeutics, Inc. Announces Clinical Device Performance Study Results for its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

An unknown large diagnostics company acquired Legacy Diagnostics Assets of Biora Therapeutics, Inc. (NasdaqGM:BIOR).

Biora Therapeutics Announces New Patents for Its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics Presents Data on the BioJet Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

First quarter 2023 earnings released: US$1.59 loss per share (vs US$1.98 loss in 1Q 2022)

Biora Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Biora Therapeutics Announces Improved Bioavailability Results for Its Systemic Delivery Platform

Biora Therapeutics Receives Compliance Letter from Nasdaq

Biora Therapeutics, Inc. Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress

Biora Therapeutics, Inc. Receives Feedback from the United States Food and Drug Administration on Its Clinical Development Plans for Its Pgn-600 Program

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Athyrium Capital Engages in Discussions with Biora Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 20%

Price target increased to US$5.00

High number of new and inexperienced directors

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering.

Biora Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biora Therapeutics, Inc. Shares Data from Device Performance Study in Ulcerative Colitis Patients

Biora Therapeutics, Inc. Shares Preclinical Data on Oral Delivery of Biologics At the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Biora Therapeutics: Checking In On The Transformation

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.65 loss in 2Q 2021)

Biora Therapeutics, Inc. Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for Its Targeted Therapeutics Platform

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for Its Targeted Therapeutics Platform

Biora Therapeutics, Inc. Announces Board Appointment

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.30 loss in 1Q 2021)

Biora Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$8.00

High number of new and inexperienced directors

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

Price target increased to US$8.00